Abstract
A major cause of death after allogeneic marrow transplantation is interstitial pneumonitis (IP), frequently associated with cytomegalovirus (CMV) infection [1]. It is presumed that most CMV infections are either acquired by transfusion of blood products or represent reactivation of a latent endogenous virus. Because the prospects for treatment of CMV are relatively remote, attention has centered on prevention. Recently, controlled trials of passive immunization for the prevention of CMV disease in bone marrow allograft recipients have been done [2–4].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
